Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bernard Bégaud is active.

Publication


Featured researches published by Bernard Bégaud.


Drug Safety | 2013

A Potential Event-Competition Bias in Safety Signal Detection: Results from a Spontaneous Reporting Research Database in France

Francesco Salvo; Florent Leborgne; Frantz Thiessard; Nicholas Moore; Bernard Bégaud; Antoine Pariente

BackgroundIn spontaneous reporting databases, reports of well-established drug-event associations may mask alerts that arise from other drugs (drug competition bias). However, a symmetrical event-competition bias has not yet been explored whereby known events may mask an association with new events for a given drug or drug class.ObjectiveThe objective of this study was to explore the effects of event-competition bias on safety signals generated from spontaneous reporting databases.MethodsThe drug classes tested included statins, oral anticoagulants, antipsychotics and HIV antiretrovirals. For each, a type A reaction was selected, and its potential competitive effect on the generation of other safety signals for the drug was explored. These were rhabdomyolysis/myopathy for statins, haemorrhage for oral anticoagulants, extrapyramidal syndrome for antipsychotics and lipodystrophy for HIV antiretrovirals. Signals of disproportionate reporting (SDRs) were detected using the case/non-case approach in the French research spontaneous reporting database (which contains reports from 1 January 1986 to 31 December 2001), before and after removing all reports concerning these competitor events. SDRs were considered as potential signals if not reported in the literature before 1 January 2002 but confirmed since.ResultsThe whole database included 207,236 reports, 4,355 of which included statins as one of the suspected drugs. The removal of reports of rhabdomyolysis/myopathy concerned 8,425 reports among which 867 involved statins. After this removal, 11 new SDRs appeared for statins that had not been detected initially. Similarly, 15 SDRs were unmasked for oral anticoagulants, six for antipsychotics and nine for HIV antiretrovirals. After literature-based assessment, five of the 41 unmasked SDRs appeared related to potential safety signals confirmed after 2002.ConclusionThis study demonstrated that a masking phenomenon resulting from an event-competition effect could occur when performing signal detection using disproportionality analyses of spontaneous reporting databases. This should be taken into account when routine signal detection is performed.


BMJ Open | 2012

Who seeks primary care for sleep, anxiety and depressive disorders from physicians prescribing homeopathic and other complementary medicine? Results from the EPI3 population survey

Lamiae Grimaldi-Bensouda; Pierre Engel; Jacques Massol; Didier Guillemot; Bernard Avouac; Gérard Duru; Anne-Marie Magnier; Michel Rossignol; F. Rouillon; Lucien Abenhaim; Bernard Bégaud

Objectives To describe and compare patients seeking treatment for sleep, anxiety and depressive disorders (SADD) from physicians in general practice (GPs) with three different practice preferences: strictly conventional medicine (GP-CM), mixed complementary and conventional medicine (GP-Mx) and certified homeopathic physicians (GP-Ho). Design and setting The EPI3 survey was a nationwide, observational study of a representative sample of GPs and their patients, conducted in France between March 2007 and July 2008. Participants 1572 patients diagnosed with SADD. Primary and secondary outcomes The patients’ attitude towards complementary and alternative medicine; psychotropic drug utilisation. Results Compared to patients attending GP-CM, GP-Ho patients had healthier lifestyles while GP-Mx patients showed similar profiles. Psychotropic drugs were more likely to be prescribed by GP-CM (64%) than GP-Mx (55.4%) and GP-Ho (31.2%). The three groups of patients shared similar SADD severity. Conclusion Our results showed that patients with SADD, while differing principally in their sociodemographic profiles and conventional psychotropic prescriptions, were actually rather similar regarding the severity of SADD in terms of comorbidities and quality of life. This information may help to better plan resource allocation and management of these common health problems in primary care.


Journal of Ethnopharmacology | 2014

Effects of Cydonia oblonga Miller extracts on blood hemostasis, coagulation and fibrinolysis in mice, and experimental thrombosis in rats.

Wenting Zhou; Adil Abdurahman; Anwar Umar; Guldiyar Iskander; Elzira Abdusalam; Bénedicte Berké; Bernard Bégaud; Nicholas Moore

INTRODUCTION Cydonia oblonga Miller (COM) is traditionally used in Uyghur medicine for the prevention of cardiovascular disease. The present study is designed to explore the effects of COM extracts on models and markers of thrombosis and related biomarkers. MATERIALS AND METHODS 20, 40, 80 mg/kg/day COM aqueous extracts and 5mg/kg/day aspirin, orally for 14 days were compared to untreated controls in mice on bleeding and clotting times, using the tail cutting and glass slide methods and for death rates in collagen-epinephrine pulmonary thrombosis, thrombolysis in vitro and euglobulin lysis time (ELT). In rats, common carotid artery FeCl3-induced thrombus and inferior vena cava thrombosis occlusion time, plasma concentrations of thromboxane B2 (TXB2) and 6-keto-prostaglandine F1α (6-keto-PGF1α) were measured. RESULTS AND CONCLUSION Compared to controls, COM extracts dose-dependently prolonged bleeding by 2.17, 2.78 and 3.63 times, vs. aspirin 2.58, and the clotting time by 1.44, 2.47 and 2.48 times, vs. aspirin 1.91. COM reduced pulmonary embolus mortality by 27, 40 and 53%, vs. 47% for aspirin. COM dose-dependently increased thrombolysis by 45, 55 and 63%, vs. 56% for aspirin, and shortened ELT to 71, 61 and 43%, vs. 43% for aspirin. In rats, venous occlusion time was prolonged. Arterial and venous thrombus weights were dose-dependently reduced in COM groups. TXB2 decreased and 6-keto-PGF1α increased with COM and aspirin, with an association between 6-keto-PGF1α/TXB2 and arterial or venous thrombus weight for all products, and for occlusion time with COM but not for aspirin. CONCLUSION We confirm the experimental effects of COM on hemostasis and thrombosis. Further exploration of putative clinical effects appear justified.


BMJ | 2012

Authors’ reply to Coyle-Gilchrist and colleagues and Bocti and colleagues

Sophie Billioti de Gage; Bernard Bégaud; Antoine Pariente

Coyle-Gilchrist and colleagues and Bocti and colleagues are directly or indirectly concerned with the possible non-causal nature of the association we found between benzodiazepines and dementia.1 2 3 We emphasise that we never concluded that this association was causal. We designed our study to go further than previously published studies by minimising possible confounding …


Mann's Pharmacovigilance | 2014

Quantitative Signal Detection and Analysis in Pharmacovigilance

Andrew Bate; Antoine Pariente; Manfred Hauben; Bernard Bégaud


Revue D Epidemiologie Et De Sante Publique | 2014

Choix du dénominateur pour les études cas-population : taux d’insuffisance hépatique aiguë ayant conduit à l’inscription sur la liste de transplantation hépatique chez des patients exposés à des anti-inflammatoires non stéroïdiens en France et inclus dans l’étude SALT

N. Moore; S. Ezgi Gulmez; Dominique Larrey; Georges-Philippe Pageaux; S. Lignot; R. Lassalle; J. Jové; A. Pariente; P. Blin; Jacques Benichou; Bernard Bégaud


European Neuropsychopharmacology | 2014

P.5.a.003 Increased risk of Alzheimer's disease in benzodiazepine long-term users: a case–control study

S. Billioti de Gage; Yola Moride; Thierry Ducruet; Tobias Kurth; Hélène Verdoux; Marie Tournier; Antoine Pariente; Bernard Bégaud


/data/revues/09249338/v29i8sS/S0924933814002296/ | 2014

Évolution au cours du temps des caractéristiques associées à la prise de psychotropes chez le sujet âgé

C. Lacueille; Bernard Bégaud; S Billioti De Gage; Marie Tournier


Value in Health | 2012

PIH64 Burden of 100 Diseases within General Practice: Results of the EPI3 Program

L. Grimaldi-Bensouda; Bernard Bégaud; F. Lert; F. Rouillon; Jacques Massol; P. Engel; Didier Guillemot; B. Avouac; Gérard Duru; Anne-Marie Magnier; Michel Rossignol; Lucien Abenhaim


Revue D Epidemiologie Et De Sante Publique | 2011

Nouvelle approche d’évaluation de la prévalence de la polyarthrite rhumatoïde et de la spondylarthrite ankylosante en France

P. Blin; M.-A. Bernard; R. Lassalle; B. Ambrosino; T. Shaeverbeke; Annie Fourrier-Réglat; Bernard Bégaud; Jacques Benichou; Cécile Droz-Perroteau; Nicholas Moore

Collaboration


Dive into the Bernard Bégaud's collaboration.

Top Co-Authors

Avatar

Antoine Pariente

Université Bordeaux Segalen

View shared research outputs
Top Co-Authors

Avatar

Jacques Massol

University of Franche-Comté

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

P. Blin

University of Bordeaux

View shared research outputs
Top Co-Authors

Avatar

R. Lassalle

University of Bordeaux

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Adil Abdurahman

Xinjiang Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge